^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors.

    Published date:
    05/19/2021
    Excerpt:
    Pts with NSCLC treated with ICIs...98 of 427 pts (23%)had HP and an additional 86 pts (20%) had progressive disease...By tumor gene alterations, HP was seen in pts with: EGFR (20/60), STK11/LKB1 (16/25); and MDM2/4 (4/7).
    DOI:
    10.1200/JCO.2021.39.15_suppl.9105
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P34.02 - Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells From Patients With Non-Small-Cell Lung Cancer

    Published date:
    01/12/2021
    Excerpt:
    For 59 patients with paired TT specimens, the expression of PD-L1 in their CTCs and TTs was determined using the immunohistochemistry....The univariate analysis of survival showed that the progression-free survival time of initial treated patients with positive PD-L1 expression in CTCs or TTs was shorter than that of those with negative PD-L1 expression in CTCs or TTs (P>0.05)...
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).

    Published date:
    05/16/2018
    Excerpt:
    PFS was positively influenced by smoking (p = 0.003) and PDL1 expression (p = 0.02) in the overall population but not for EGFR-mutant….ICI has inconstant efficacy in NSCLC harboring activating mutation.
    DOI:
    10.1200/JCO.2018.36.15_suppl.9010